Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Major Shareholder Rtw Investments, Lp Buys 1,557,346 Shares

0

Major shareholder of Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Rating), Rtw Investments, Lp, acquired 1,557,346 shares of the company in a transaction dated Wednesday, September 7. The shares were purchased at an average cost of $8.71 per share, for a total transaction of $13,564,483.66. Following the completion of the acquisition, the insider now directly owns 4,315,102 shares of the company, valued at $37,584,538.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Major shareholders who own more than 10% of a company’s stock are required to disclose their sales and purchases to the SEC.

Milestone Pharmaceuticals is trading up 2.1%

Shares of NASDAQ MIST were up $0.18 during Friday trading hours, hitting $8.71. 220,430 shares of the company were traded, with an average volume of 114,259. The stock has a market capitalization of $261.40 million, a price-earnings ratio of -5.84 and a beta of 2.65. . The company’s 50-day moving average price is $7.17 and its 200-day moving average price is $6.36. Milestone Pharmaceuticals Inc. has a 12 month minimum of $3.98 and a 12 month maximum of $9.00.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) last reported quarterly earnings data on Wednesday, August 10. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Equity analysts expect Milestone Pharmaceuticals Inc. to post EPS of -1.53 ​​for the current year.

Institutional entries and exits

pixel

A d Trader

Buy alert for $2 coin

The man who picked Bitcoin in 2014 when it was trading for just $369…chose Ethereum in 2016 when it was trading for just $7, now believes a tiny $2 coin is on the way to FLY AWAY! So if you missed out on Bitcoin and Ethereum…this could be your last chance for mind-boggling crypto gains. Learn how to seize this huge opportunity.

A number of hedge funds have recently changed their holdings in the company. Acuta Capital Partners LLC increased its stake in Milestone Pharmaceuticals by 20.3% in the second quarter. Acuta Capital Partners LLC now owns 457,200 shares of the company valued at $2,812,000 after purchasing an additional 77,200 shares during the period. Millennium Management LLC increased its stake in Milestone Pharmaceuticals by 5.4% in the second quarter. Millennium Management LLC now owns 1,358,362 shares of the company valued at $8,069,000 after purchasing an additional 69,439 shares during the period. BNP Paribas Arbitrage SA acquired a new stake in Milestone Pharmaceuticals in the first quarter worth approximately $25,000. PDT Partners LLC acquired a new stake in Milestone Pharmaceuticals in the first quarter worth approximately $65,000. Finally, Dimensional Fund Advisors LP increased its holdings in Milestone Pharmaceuticals by 17.4% in the first quarter. Dimensional Fund Advisors LP now owns 61,743 shares of the company valued at $397,000 after purchasing an additional 9,165 shares during the period. 69.44% of the shares are held by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

(Get an evaluation)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, is focused on the development and commercialization of cardiovascular drugs. The company is developing etripamil, a new channel blocker, which is in a phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and a phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Recommended Stories

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Milestone Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Milestone Pharmaceuticals was not on the list.

Although Milestone Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.